Drugs / CU-10101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06744569 | Sep 2024 → Sep 2026 overdue | atopic eczema | Cutia Therapeutics (Wuxi) Co., Ltd | Enrolling by invitation | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-05-30 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS APPROVED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗ |
| 2024-03-26 | Cutia Therapeutics（Wuxi）Co.,Ltd | Regulatory VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS ACCEPTED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION cutiatx.com ↗
The board of directors (the “Board ”) of the Company is pleased to announce that the investigational new drug (IND) application of CU-10101 (topical novel small molecule agent) of the Group, for the treatment of mild to moderate atopic dermatitis has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of the People ’s Republic of China. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CU-10101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06744569 ↗ |
| Route | Topical | “applied to the skin lesion sites” NCT06744569 ↗ |